Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Rang in Aktien #17309
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Aktienkurs
$1.21
Marktkapitalisierung
$248.41M
Veränderung (1 Tag)
4.11%
Veränderung (1 Jahr)
79.12%
Land
TW
Handel TWi Biotechnology, Inc. (6610)

Kategorie

Aktien-Split-Historie für TWi Biotechnology, Inc. (6610)
Die Aktie TWi Biotechnology, Inc. (Symbol: 6610) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Sep 02, 2026 statt.
Eine 6610-Aktie, die vor dem Sep 02, 2026 gekauft wurde, entspricht heute 0 6610-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH